Polaris Group appointed Chien-Hsing Chang, Vice President of R&D, IMMUNOMEDICS Inc. as Chief Strategy Officer effective June 20, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
71.3 TWD | +0.28% | +1.28% | -5.69% |
May. 14 | Polaris Group Announces Change of the Member of Compensation Committee | CI |
2023 | Polaris Group Announces the Appointment of K Evin Wu | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.69% | 1.63B | |
+29.50% | 49.18B | |
+1.05% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.71% | 26.09B | |
-22.68% | 18.71B | |
+8.18% | 13.26B | |
+32.23% | 12.32B | |
-0.78% | 11.99B |
- Stock Market
- Equities
- 6550 Stock
- News Polaris Group
- Polaris Group Appoints Chien-Hsing Chang as Chief Strategy Officer Effective June 20, 2023